Lauren Pommert

Dr. Lauren Pommert

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
LPLauren Pommert
Lauren Pommert
ESEric S. Schafer
Eric S. Schafer
JMJemily Malvar
Jemily Malvar
NGNathan Gossai
Nathan Gossai
EFEllynore Florendo
Ellynore Florendo
MBMichael J. Burke
Michael J. Burke

25 November 2019 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
RPRachel Phelan
Rachel Phelan
HEHesham Eissa
Hesham Eissa
KBKerri Becktell
Kerri Becktell
NBNeel Bhatt
Neel Bhatt
MKMatthew Kudek
Matthew Kudek
KBKevin Scott Baker
Kevin Scott Baker

21 June 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
ESEric S. Schafer
Eric S. Schafer
KCKaren Chao
Karen Chao
ASAlexandra M. Stevens
Alexandra M. Stevens
EJEunji Jo
Eunji Jo
SHSusan G. Hilsenbeck
Susan G. Hilsenbeck
MBMichael J. Burke
Michael J. Burke

3 August 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
ZTZachary L. Taylor
Zachary L. Taylor
TMTamara P. Miller
Tamara P. Miller
EPEthan Poweleit
Ethan Poweleit
NDNicholas P. DeGroote
Nicholas P. DeGroote
LPLauren Pommert
Lauren Pommert
Laura B. RamseyLaura B. Ramsey
Laura B. Ramsey
The MTXPK.org webtool was launched in December 2019 and was developed to facilitate model‐informed supportive care and optimal use of glucarpidase following the administration of high‐dose methotrexate (HDMTX). One limitation identified during the original development of the MTXPK.org tool was the perceived generalizability because the modeled population comprised solely of Nordic pediatric patients receiving 24‐h infusions for the treatment of acute lymphoblastic leukemia. The goal of our study is to describe the pharmacokinetics of HDMTX from a diverse patient population (e.g., races, ethnicity, indications for methotrexate, and variable infusion durations) and identify meaningful factors that account for methotrexate variability and improve the model's performance. To do this, retrospectively analyzed pharmacokinetic and toxicity data from pediatric and adolescent young adult patients who were receiving HDMTX (>0.5 g/m2) for the treatment of a cancer diagnosis from three pediatric medical centers. We performed population pharmacokinetic modeling referencing the original MTXPK.org NONMEM model (includes body surface area and serum creatinine as covariates) on 1668 patients, 7506 administrations of HDMTX, and 30,250 concentrations. Our results support the parameterizations of short infusion duration (<8 h) and the presence of Down syndrome on methotrexate clearance, the parameterization of severe hypoalbuminemia (<2.5 g/dL) on the intercompartmental clearance (Q2 and Q3), and the parameterization of pleural effusion on the volume of distribution (V1 and V2). These novel parameterizations will increase the generalizability of the MTXPK.org model once they are added to the webtool.

31 July 2024 in British Journal of Haematology
Verified
Journal Article
Open access
FLFrancis R. LeBlanc
Francis R. LeBlanc
EBErin H. Breese
Erin H. Breese
KBKaren C. Burns
Karen C. Burns
ECEllen K. Chang
Ellen K. Chang
LJLaQuita M. Jones
LaQuita M. Jones
LPLauren Pommert
Lauren Pommert
Summary: Venetoclax (VEN) combined with hypomethylating agents (HMA) decitabine or azacitidine is used for adult acute myeloid leukaemia (AML), but its application in paediatric, adolescent and young adult (AYA) AML lacks prospective studies. We performed a retrospective chart review of paediatric and AYA AML patients treated with HMA + VEN at Cincinnati Children's Hospital Medical Centre. Twenty‐seven patients received 30 HMA + VEN treatment courses for relapsed/refractory (R/R, n = 21) or newly diagnosed (n = 9) AML due to ineligibility for intensive chemotherapy. The R/R cohort had high‐risk cytomolecular genetic alterations and prior extensive treatments, with 50% (n = 9) of relapse patients (n = 18) having undergone haematopoietic stem cell transplantation (HSCT). Venetoclax treatment using the 400 mg adult exposure‐equivelant dosing (AED) had a median duration of 21 days (range 7–30 days). Grade 3–4 toxicities included neutropenia (90%), anaemia (64%), thrombocytopenia (64%) and febrile neutropenia (44%). The overall complete remission (CR)/CR with incomplete blood count recovery (CRi) rate was 73% (77% minimal residual disease [MRD] negativity <0.1%), with 60% undergoing HSCT. Among newly diagnosed patients (n = 9), 89% achieved CR/CRi (78% MRD negativity) and 78% proceeded to HSCT. The R/R cohort (n = 21) showed a 67% CR/CRi rate (71% MRD negativity), with 52% undergoing HSCT. These findings support the safety and efficacy of HMA + VEN in paediatric/AYA AML, indicating it as a viable option for patients unfit for intensive chemotherapy. Further studies are necessary to determine optimal venetoclax dosing, chemotherapy combinations and pharmacokinetics in this population.

26 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LPLauren Pommert
Lauren Pommert
TCTodd M Cooper
Todd M Cooper
RGRobert B. Gerbing
Robert B. Gerbing
LBLisa Brodersen
Lisa Brodersen
MLMichael Loken
Michael Loken
EKEdward A. Kolb
Edward A. Kolb
International Working Group (IWG) and European LeukemiaNet (ELN) response definitions are utilized to evaluate the efficacy of new agents for childhood acute myeloid leukemia (AML) for regulatory purposes. However, these criteria are not consistent with definitions used in pediatric AML trials or with standard pediatric practice to proceed with subsequent therapy cycles prior to IWG/ELN-defined count recovery. We retrospectively analyzed data from the two most recent Phase 3 pediatric AML clinical trials conducted by the Children’s Oncology Group (COG) to assess the incidence, timing, and prognostic significance of count recovery following induction chemotherapy. Of the patients with fewer than 5% bone marrow blasts at the end of first induction, 21.5% of patients proceeded to a second induction cycle prior to achieving ANC ≥ 500 cells/μL and platelets ≥ 50,000 cells/μL, both well below the IWG/ELN thresholds of ANC > 1000 cells/μL and platelets > 100,000 cells/μL. In these two sequential childhood AML Phase 3 trials, neither ANC nor platelet recovery predicted survival. Intensification of treatment through the initiation of subsequent therapy cycles prior to attainment of IWG/ELN-defined CR is common practice in clinical trials for children with AML, suggesting that updated response definitions are needed for pediatric AML.